Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.16
Views: 2932
Rating:

Prof John Robertson - University of Nottingham, Nottingham, UK

Prof Robertson speaks with ecancer at ESMO 2016 about the results of the phase III FALCON trial, which found fulvestrant significantly increased progression-free survival (PFS) in women with hormone-receptor-positive advanced breast cancer, and particularly those with less aggressive lower-volume disease.

He outlines the research that led to this trial, as discussed at SABCS 2014, and explains what these results mean for care going forwards

These results were also discussed by Dr Matthew Ellis, who spoke with ecancer here.

Read the news story for more.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation